A new retraction notice in the Journal of Applied Physiology gives only a hint at the problems in the paper, but what it does say has led us to a story about one of its co-authors.
Here’s the notice, from a team at Duke: Continue reading Former Duke researcher charged with embezzlement has a paper retracted
We’ve written before about retractions for cell lines that turn out not to be what researchers thought they were. In a few cases, that has involved contamination by HeLa cells, named for Henrietta Lacks. Today, we note the retraction of a paper whose authors, from Taiwan, thought they were using human muscle cells that line blood vessels when they were actually studying such cells from rat embryos.
Here’s the notice in the British Journal of Nutrition for “Molecular mechanism of green microalgae, Dunaliella salina, involved in attenuating balloon injury-induced neointimal formation”: Continue reading Cell line mixup causes retraction of paper on blood vessel damage
Yesterday we reported on the retraction for data misuse and plagiarism of a 21-year-old paper on sex and female cancer patients. Turns out we missed a couple of rather interesting details about the authors of the pulled article.
One tidbit, for example, is that one of them, Willibrord Weijmar Schultz, is science royalty, having been a member of a team that won the 2000 Ig Nobel prize in medicine. Their heralded study, “Magnetic resonance imaging of male and female genitals during coitus and female sexual arousal,” published in 1999 in the BMJ: An inside-the-MRI look at the human body having sex. Continue reading Authors of retracted sex paper won Ig Nobel for MRI study of coitus — and had another retraction
Leukemia & Lymphoma has retracted 2004 paper by a group of authors in Mexico after concluding that, well, the article never should have been accepted to begin with.
The article, “Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome,” came from oncologists at the National Medical Center. Its abstract (still available on Medline) states: Continue reading Lacking “scientific and analytical rigor,” 8-year-old lymphoma paper falls to retraction
Here’s one for the way-back machine.
The Annual Review of Sex Research (which is a supplement to the Journal of Sex Research) has retracted a 1992 paper by a group of researchers who lifted much of their analysis from two even older articles by another scholar. At 21 years post-publication, this is one of the oldest — but not the record-oldest — retractions we’ve covered to date.
The pulled paper, “Sexuality and cancer in women,” came from Willibrord C. M. Weijmar Schultz, Harry B. M. Van de Wiel, Daniela E. E. Hahn, and Mels F. Van Driel. (Weijmar Schultz and Van de Wiel are co-authors of this rather curious passage about the appropriateness of sexual contact between doctors and patients:
Continue reading 21-year-old article on the sex lives of women with cancer retracted for data misuse
Last month, Ivan met David Vaux at the 3rd World Conference on Research Integrity in Montreal. David mentioned a retraction he published in Nature, and we thought it would be a great guest post on what it’s like to retract one of your own papers in an attempt to clean up the literature.
In September 1995 Nature asked me to review a manuscript by Bellgrau and co-workers, which subsequently appeared. I was very excited by this paper, as it showed that expression of CD95L on Sertoli cells in allogeneic mismatched testes tissue transplanted under the kidney capsule was able to induce apoptosis of invading cytotoxic T cells, thereby preventing rejection. As I wrote in a News and Views piece, the implications of these findings were enormous – grafts engineered to express CD95L would be able to prevent rejection without generalized immunosuppression.
In fact, I was so taken by these findings that we started generation of transgenic mice that expressed CD95L on their islet beta cells to see if it would allow islet cell grafts to avoid rejection and provide a cure for diabetes in mismatched recipients.
Little did we know that instead of providing an answer to transplant rejection, these experiments would teach us a great deal about editorial practices and the difficulty of correcting errors once they appear in the literature. Continue reading Why I retracted my Nature paper: A guest post from David Vaux about correcting the scientific record
Our mothers told us that if we used the masterbatch process, we’d go blind. And what better way to gather some updates to recent posts than to include one that involves said masterbatch process?
First, a retraction John Spevacek noticed when he tried clicking on the link in a Journal of Applied Polymer Science retraction we’d covered: Continue reading A masterbatch: More polymer retractions, gerontology journal lifts paywall, Microbiology notices appear
A cancer researcher whose work was the subject of a lawsuit has retracted his fifth paper, this one from 2004.
Robert Getzenberg, formerly of the University of Pittsburgh and Johns Hopkins, has had two papers on prostate cancer biomarkers retracted, and two on colon cancer. The newly retracted paper is about a potential bladder cancer biomarker.
Here’s the notice from Clinical Cancer Research: Continue reading A fifth retraction for former Pitt and Hopkins oncology researcher Getzenberg
The International Journal of Human-Computer Interaction has retracted four papers about virtual reality for reasons that aren’t quite clear.
The common author of the studies is Dong-Hee Shin of Seoul’s Sungkyunkwan University. Here’s the retraction notice, which is signed by journal editors-in-chief Gavriel Salvendy and Julie Jacko: Continue reading Four papers about gaming and virtual worlds become more virtual and less reality as they’re retracted
In what could be a significant blow to a major pharmaceutical company, Nature Medicine is reportedly set to retract a 2010 article by a group of researchers affiliated with a Chinese arm of the drug giant GlaxoSmithKline.
We’re not the first to report the news — you can read coverage of it on In the Pipeline and Pharmalot, for starters — which includes the revelation that Glaxo has fired Jingwu Zang, a co-author of the suspect paper and former senior vice president and head of research and development at the Shanghai facility: in other words, a big fish. (Big enough to have a profile in, well, Nature Reviews Drug Discovery.)
Pharmalot has quoted a Glaxo spokeswoman: Continue reading Glaxo asks Nature Medicine to retract paper by fired company scientist